About: http://data.cimple.eu/news-article/98254991ab03de0bd96074838d75db8721e424683adf61715e26f7aa

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/98254991ab03de0bd96074838d75db8721e424683adf61715e26f7aa Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	A new preliminary study -- based on a small sample -- has suggested that people previously infected by the Covid-19 variant identified in South Africa may have better immunity against other coronavirus mutations, experts said Wednesday. The findings, from a yet to be peer-reviewed research by the team of South African scientists who discovered the 501Y.V2 variant, raise hopes that vaccines modelled on the strain could protect against future mutations. Only four percent of a sample of 55 patients who had 501Y.V2 failed to neutralise infection from the original coronavirus variant, according to data presented by a cohort of scientists under the Network Genomic Surveillance South Africa (NGS-SA). Identified late last year, the variant became the dominant strain in the African nation worst hit by the pandemic, fuelling the second wave of infections and delaying the start of vaccinations in February. Top virologist Tulio de Oliveira, told a video conference attended by senior government ministers that "the 501Y.V2 can produce a high level of antibodies that can neutralise itself," he said, adding that the immune response outperforms previous variants. Health Minister Zweli Mkhize told the same meeting that the discovery was "good news for all" as it presented a huge boost to the control of the pandemic. Coronavirus mutations -- some more contagious -- had put a damper on global vaccination programmes after existing shots were found to offer less protection against them. Manufacturers have in recent weeks raced to tweak their formulas in response to the spread of newer variants. US biotechnology company Moderna last week said it will begin in mid-March a clinical trial of a version of its vaccine specific to the South Africa variant. Top government advisor and leading epidemiologist Salim Abdool Karim explained that shots developed by Pfizer/BioNTech and Moderna uses mRNA technology to elicit antibody production, and that the recent development bodes well for achieving immunity. "These findings are basically telling us that we have a good prospect of success if we make a vaccine based on it," he said. ho/sn/pma
schema:headline	Study suggests S.Africa variant could offer better immunity
schema:mentions	Epidemiology Biotechnology Virology Peer review USA Gymnastics Clinical trial Antibody Immune system Messenger RNA South Africa Pandemic Pfizer Vaccine Coronavirus Coronavirus disease 2019 Salim Abdool Karim Tweak programming environment Zweli Mkhize
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-03-03 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	80 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software